Transplant oncology: an evolving field in cancer care
Simple Summary Transplant oncology is an emerging concept of cancer treatment with a
promising prospective outcome. The application of oncology, transplant medicine, and …
promising prospective outcome. The application of oncology, transplant medicine, and …
Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view
M Abdelrahim, A Esmail, A Saharia, A Abudayyeh… - Cancers, 2022 - mdpi.com
Simple Summary Hepatocellular carcinoma is the second most common cause of cancer-
related deaths and accounts for over eighty percent of primary liver cancers worldwide …
related deaths and accounts for over eighty percent of primary liver cancers worldwide …
Immunotherapy use prior to liver transplant in patients with hepatocellular carcinoma
SM Woo, AV Kimchy, LM Sequeira, CS Dorris, AR He… - Current oncology, 2022 - mdpi.com
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide, and its incidence has increased rapidly in the United States over the past two …
worldwide, and its incidence has increased rapidly in the United States over the past two …
Hepatocellular carcinoma: The role of immunotherapy and transplantation in the era of transplant oncology
S Alghamdi, W Al-Hamoudi - Cancers, 2023 - mdpi.com
Simple Summary Hepatocellular carcinoma (HCC) is a common cause of cancer-related
deaths worldwide. During the early stages of the disease, HCC can be treated with surgery …
deaths worldwide. During the early stages of the disease, HCC can be treated with surgery …
Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma
A Chen, Z Yu, N Ma, X Lu, Y Zhang, W Xu… - Cancer Immunology …, 2024 - Springer
T-cell receptor (TCR) engineered T-cell therapy has recently emerged as a promising
adoptive immunotherapy approach for tumor treatment, yet hindered by tumor immune …
adoptive immunotherapy approach for tumor treatment, yet hindered by tumor immune …
Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a …
Background Hepatocellular carcinoma (HCC) is one of the cancers with the highest
morbidity and mortality. Sorafenib used to be the main treatment for unresectable HCC …
morbidity and mortality. Sorafenib used to be the main treatment for unresectable HCC …
An overview: management of patients with advanced hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has constituted a significant health burden worldwide, and
patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver …
patients with advanced HCC, which is stage C as defined by the Barcelona Clinic Liver …
[HTML][HTML] Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated mortality
worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in …
worldwide. HCC is an inflammation-associated immunogenic cancer that frequently arises in …
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study
Introduction Immunotherapy is a new promising treatment for patients with advanced
hepatocellular carcinoma (HCC), but is costly and potentially associated with considerable …
hepatocellular carcinoma (HCC), but is costly and potentially associated with considerable …
Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma
Y Nie, H Fan, J Li, X Lei, T Zhang, Y Wang… - The FASEB …, 2022 - Wiley Online Library
The prognostic value of immune cells in tertiary lymphoid structures (TLSs) remains unclear
in hepatocellular carcinoma (HCC). Here, 59 of 145 patients had TLSs in training set, 48 of …
in hepatocellular carcinoma (HCC). Here, 59 of 145 patients had TLSs in training set, 48 of …